Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Eledon Pharmaceuticals Inc (ELDN) USD0.001

Sell:$16.35 Buy:$16.50 Change: $0.04 (0.24%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Change: $0.04 (0.24%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Change: $0.04 (0.24%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eledon Pharmaceuticals, Inc., formerly Novus Therapeutics, Inc., is a pharmaceutical company. The Company is focused on developing targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases. The Company’s lead product candidate, AT-1501, is a humanized monoclonal antibody (mAb), designed to target CD40 Ligand (CD40L), a molecule expressed on the surface of human immune system T cells. The central role of CD40/CD40L signaling in generating pro-inflammatory responses makes it an attractive candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance, and neuroinflammation. Blocking the activation of the CD40L pathway ameliorates disease progression and pathology in preclinical models of autoimmunity and prevents acute and long-term allograft transplant rejection in multiple animal species.

Contact details

19900 Macarthur Blvd Ste 550
United States
+1 (949) 2388090

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$236.63 million
Shares in issue:
14.31 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Keith Katkin
    Independent Chairman of the Board
  • Steven Perrin
    President, Chief Scientific Officer
  • David-Alexandre Gros
    Chief Executive Officer, Director
  • Jon Kuwahara
    Chief Financial Officer, Chief Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.